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ABSTRACT
Introduction: The rate of adverse renal events
has been shown to be higher in patients treated
with lesinurad plus a xanthine-oxidase inhi-
bitor (XOI) than in patients treated only with a
XOI. We reassessed the risks for various adverse
renal events from a different perspective and
devised a hypothesis to explain the results.
Methods: We used data from phase 3 trials that
were publicly available from the full prescribing
information document and estimated the rela-
tive risk and the number needed to treat for
increased serum creatinine (sCri), renal failure,
and renal lithiasis. We examined these risks for
each treatment group and the risks stratified by
estimated glomerular filtration rate (eGFR).
Results: Overall, the relative risk for sCri was
[1.0 with the 400 mg/day dose of lesinurad
and higher with the 200 mg/day dose, but it was
\1.0 for both lithiasis and renal failure with
the 200 mg/day dose. The relative risk was only
statistically significant for sCri with the highest
dose of lesinurad. When results stratified by
eGFR were considered, the rates of adverse
events increased with declining renal function,
but the relative risks decreased in parallel, as the
rate of adverse events increased much more in
the placebo arm than in the active arm
(200 mg/day dose). Indeed, the relative risk was
only significant for the highest dose of lesinurad
in patients with normal eGFR.
Conclusion: The rate of sCri events was higher
in patients treated with both lesinurad and a XOI
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rather than a XOI alone. This rate was found to
increase with decreasing eGFR, but as it does in
for both active and placebo armsthe relative risk
is not different from that observed in the placebo
arms in the labeled 200 mg/daydose. This may be
explained by pathophysiological changes that
develop in chronic kidney disease.
Keywords: Creatinine increase; Gout;
Lesinurad; Safety; Relative risk; Renal failure;
Renal lithiasis
INTRODUCTION
Lesinurad is a selective uric acid reabsorption
inhibitor (SURI) medication that was recently
approved by the European Commission fol-
lowing a positive evaluation from the European
Medicines Agency (EMA) of the European
Union and the United States Food and Drug
Administration (FDA) [1]. Lesinurad exerts its
urate-lowering action by selectively inhibiting
urate transporters (principally URAT-1 and
OAT-4) in the proximal renal tubule and
blocking uric acid reabsorption, thereby
increasing net uric acid renal excretion [2].
The safety profile panel established during
the clinical development of lesinurad included
renal events, as would be expected for any uri-
cosuric medication. Renal events were classified
as increases in serum creatinine (sCr) concen-
trations above baseline, renal failure (which
encompassed a broad range of events, including
acute or chronic renal failure and acute pre-re-
nal failure), or nephrolithiasis. Renal events,
and specifically increases in sCr concentration,
were more frequent in patients on lesinurad
than in those on a placebo (PBO), with a dose-
dependent relationship [3], and these events
were more common in patients who did not
receive a xanthine oxidase inhibitor (XOI) while
on lesinurad therapy [4] and in those with
moderate kidney impairment [5]. These find-
ings led the EMA and FDA to approve lesinurad
only when used in combination with a XOI and
at a dose of 200 mg/day, and to recommended
that it should/must not be initiated in patients
with an estimated glomerular filtration rate
(eGFR) below 45 mL/min/1.73 m2 (summary of
product characteristics or SmPC, FDA) [6] or
30 mL/min/1.73 m2 (SmPC, EU) [7] per minute.
Intriguingly and importantly, even though
elevations in sCR were more common in lesinu-
rad-treated patients than in those receiving a
placebo, the incidence rates of renal failure and
renal nephrolithiasis did not differ between these
groups, although patients with a previous history
of renal lithiasis were not excluded [8]. While
several hypotheses have been proposed for the
development of elevated sCR in lesinurad-treated
patients, there is no widely accepted explanation
for this occurrence. Consequently, recommen-
dations are lacking in risk assessments of patients
who may be at risk of adverse renal events when
treated with lesinurad combination therapy.
Our objective was to reassess the relative
risks of various adverse renal events in lesinu-
rad-treated patients from three pivotal placebo-
controlled combination clinical trials stratified
according to renal function; to review, critique,
and attempt to explain the results; and to pro-
pose monitoring strategies.
METHODS
We analyzed data from three major phase 3
clinical trials that tested the efficacy and safety
of lesinurad in clinical practice. Incidence rates
of adverse renal events were derived from
Tables 2 and 3 in the full prescribing informa-
tion for Zurampic [6].
Table 2 of the prescribing information shows
data on the incidence rates of adverse renal events
in all three major placebo-controlled clinical
studies (CLEAR 1, CLEAR2, and CRYSTAL) in
which lesinurad in combination with a XOI (ei-
ther allopurinol or febuxostat) was compared with
XOI alone [9–11]. Adverse renal events were
defined as follows: (1) increased blood creatinine,
defined as a greater than 1.5-fold increase in sCr as
compared to the baseline measurement at trial
entry; (2) renal failure (a composite term that
described any occurrence of acute or chronic renal
failure and acute prerenal failure); and (3)
nephrolithiasis. The three studies together pro-
vided 516, 511, and 510 patients in the XOI ?
PBO, XOI ? lesinurad 200 mg/day, and
XOI ? lesinurad 400 mg/day groups, respectively.
102 Rheumatol Ther (2019) 6:101–108
Table 3 of the SmPC for Zurampic includes
data on the occurrence of adverse events in all
three clinical trials according to study arm
(XOI ? PBO, n = 510; XOI ? lesinurad
200 mg/day, n = 509; and XOI ? lesinurad
400 mg/day, n = 508) and stratified by baseline
renal function category (C 90, C 60 to \ 90,
C 30 to\60 mL/min/1.73 m2).
Statistical Analysis
We determined the patient-year exposure for
each study arm from a recently published report
on the safety of lesinurad [3] as 408, 396, and 390
patient-years, respectively. These values were
then used to compute the incidence rate of each
adverse renal event stratified by GFR category
(C 90 mL/min, C 60 to \ 90 mL/min, C 30 to
\60 mL/min/1.73 m2) in each treatment arm.
Risk ratios (RRs) and numbers needed to treat
(NNTs) were calculated to determine the impact
of each treatment on the rates of each specified
adverse renal event. Harm was defined as RR[1
and benefit as RR\ 1. Calculations were per-
formed using the MedCalc software (Medcalc
Software bvba, Ostend, Belgium, https://www.
medcalc.org/calc/relative_risk.php). These
analyses were repeated to determine the RRs of
adverse renal events stratified by kidney func-
tion. When the RR for a study cannot be cal-
culated because there are no events in the
control group of a study and the standard errors
cannot be computed, it is customary to add 0.5
to each cell of the 2 9 2 contingency table [12].
Compliance with Ethics Guidelines
Data were retrieved from a public resource: the
full prescribing information for Zurampic. This
article does not contain any studies with
human participants or animals performed by
any of the authors.
RESULTS
The incidence of increased sCr was numerically
higher among patients allocated to LES 200 mg
daily than among patients allocated to a
placebo (4.3% vs. 2.3% respectively). The cor-
responding RR (1.85, 0.93–3.70) was not statis-
tically significant (Table 1). In contrast, patients
allocated to the LES 400 mg dose showed a sig-
nificantly higher incidence of increased sCR
than patients on a placebo, along with a statis-
tically significant RR of 3.37 (1.79–6.35)
(Table 1).
On the other hand, the incidence rates for
renal failure and nephrolithiasis were numeri-
cally lower for the 200 mg daily dose vs. PBO,
but this was not a statistically significant dif-
ference. Similarly, patients allocated to the LES
400 mg dose experienced rates of renal failure
and nephrolithiasis that were not significantly
different from those in the placebo arm
(Table 1). The analysis of adverse renal events
according to eGFR category is presented in
Table 2. For each GFR category, the rate of
increased sCR was numerically higher for the
LES 200 mg group than for the placebo arm (3.0,
3.8, and 6.9 vs. 0.6, 1.7, and 5.9 for patients in
the categories CrCl C 90, CrCl C 60 to B 90,
and CrCl C 30 to B 60 mL/min, respectively)
but there were no statistically significant dif-
ferences. Intriguingly, the RR of increased sCR
decreased with worsening GFR, from 5.34 for
patients with CrCl C 90 mL/min to 1.17 for
patients with CrCl C 30 to B 60 mL/min; the
number needed to treat was over 100 for the
latter group. Furthermore, analysis of the RR of
renal failure revealed a similar pattern, with the
RR decreasing from 6.30 in patients with
CrCl C 90 mL/min to 0.40 for patients with
CrCl C 30 to B 60 mL/min. The RR of renal
failure for the LES 200 mg group versus the
placebo group was not statistically significant.
Compared to the placebo group, patients
treated with XOI plus LES 400 mg daily pre-
sented significantly higher incidence rates of
increased sCR (5.9, 9.9, and 10.9 vs. 0.6, 1.7,
and 5.9 for patients in the categories
CrCl C 90 mL, CrCl C 60 to B 90, and CrCl
C 30 to B 60 mL/min, respectively). Differences
between groups did not reach statistical signif-
icance in the lower estimated glomerular filtra-
tion rate strata, as the magnitude of the risk
ratio decreased with worsening GFR, from 10.64
(1.40–81.03) to 5.64 (1.97–16.18) to 1.83
(0.69–4.84). A similar pattern was observed for
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renal failure. Figure 1 provides a visual repre-
sentation of the incidence of increased sCR and
the corresponding risk ratio for each treatment
allocation stratified by GFR category.
DISCUSSION
Using data released publicly for use by health-
care providers [6], this analysis found that the
rate of adverse renal events was not significantly
different for the LES 200 mg group and the
placebo group. While the incidence of increased
sCR showed a modest increase for the LES
200 mg group as compared to the placebo
group, the incidence rates of renal outcomes
other than increased serum creatinine (sCri:
renal failure and nephrolithiasis) were numeri-
cally lower for the LES 200 mg arm than for the
placebo arm, with none of these differences
between groups being statistically significant. In
contrast, treatment with the higher LES 400 mg
dose yielded significantly higher rates of
increased sCR compared to the placebo group,
but—surprisingly—no significantly increased
risk of renal failure of nephrolithiasis. In gen-
eral, adverse renal event rates were lowest
among patients with normal renal function
rather than among those with decreased GFR.
However, we observed that the rate of adverse
renal events with increased sCR rose at a faster
rate in the placebo arm than in the LES 200 mg
and 400 mg arms with worsening GFR, leading
to a reduction in the relative risk.
It should be noted that while the elevation of
serum creatinine from the baseline was mea-
sured as part of a safety analysis performed by
the sponsor, clinical diagnoses were made by the
investigators and compiled using predefined
preferred terms to compile renal safety reports
and included as supplemental material in [3].
Another limitation inherent to this analysis is
that it is not a meta-analysis. While such a meta-
analysis including five clinical trials was recently
reported [13], it did not provide any fresh per-
spective on the optimal clinical approach to the
safety of lesinurad or insight into pathophysio-
logical mechanisms. Another limitation of our
study is the fact that we could only use publicly
available data compiled from phase 3 trials, and
that the number of events was small.
Therefore, to evaluate the risk of adverse
renal events between the placebo and active
arms, we employed the relative risk or risk ratio,
Table 1 Overall incidence rates of adverse renal events in phase III clinical trials comparing lesinurad plus XOI to placebo
plus XOI
XOI 1 PBO
N = 516
XOI 1 LES200
N = 511
RR (95% CI) NNT p
Events (%) Events (%)
Increased sCr 12 (2.3) 22 (4.3) 1.85 (0.93–3.70) - 51 0.081
Renal failure 11 (2.1) 6 (1.2) 0.55 (0.20–1.48) ? 104 0.236
Nephrolithiasis 9 (1.7) 3 (0.6) 0.34 (0.09–1.24) ? 86 0.101
XOI 1 PBO
N = 516
XOI 1 LES400
N = 510
RR (95% CI) NNT p
Events (%) Events (%)
Increased sCr 12 (2.3) 40 (7.8) 3.37 (1.79–6.35) - 18 \ 0.000
Renal failure 11 (2.1) 18 (3.5) 1.65 (0.79–3.47) - 72 0.182
Nephrolithiasis 9 (1.7) 13 (2.5) 1.46 (0.63–3.39) - 124 0.377
Increased sCr serum creatinine[1.5 9 baseline value, RR relative risk or risk ratio (absolute risk of an event in the active
group/absolute risk for event in the control group), NNT number needed to treat (- for harm, ? for beneﬁt), XOI
xanthine oxidase inhibitor, PBO placebo, LES200 lesinurad 200 mg once a day, LES400 lesinurad 400 mg once a day
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Table 2 Analysis of adverse renal events in patients stratiﬁed by estimated glomerular ﬁltration rate
CrCl ‡ 90 mL/min XOI 1 PBO
N = 510
XOI 1 LES200
N = 509
RR (95% CI) NNT p
Events (%)
N = 180
Events (%)
N = 200
Increased sCr 1 (0.6) 6 (3.0) 5.34 (0.65–43.98) - 41 0.199
Renal failure 0 3 (1.5) 6.30 (0.32–121.21) - 29 0.222
CrCl ‡ 60 to < 90 mL/min XOI 1 PBO
N = 510
XOI 1 LES200
N = 509
RR (95% CI) NNT p
Events (%)
N = 229
Events (%)
N = 208
Increased sCr 4 (1.7) 8 (3.8) 2.20 (0.67–7.21) - 48 0.192
Renal failure 4 (1.7) 1 (0.5) 0.28 (0.03–2.44) ? 79 0.247
CrCl ‡ 30 to < 60 mL/min XOI 1 PBO
N = 510
XOI 1 LES200
N = 509
RR (95% CI) NNT p
Events (%)
N = 101
Events (%)
N = 101
Increased sCr 6 (5.9) 7 (6.9) 1.17 (0.40–3.35) - 101 0.775
Renal failure 5 (5.0) 2 (2.0) 0.40 (0.08–2.01) ? 49 0.267
CrCl ‡ 90 mL/min XOI 1 PBO
N = 510
XOI 1 LES400
N = 508
RR (95% CI) NNT p
Events (%)
N = 180
Events (%)
N = 203
Increased sCr 1 (0.6) 12 (5.9) 10.64 (1.40–81.03) - 19 0.022
Renal failure 0 7 (3.4) 13.31 (0.76–231.40) - 29 0.0756
CrCl ‡ 60 to < 90 mL/min XOI 1 PBO
N = 510
XOI 1 LES400
N = 508
RR (95% CI) NNT p
Events (%)
N = 229
Events (%)
N = 213
Increased sCr 4 (1.7) 21 (9.9) 5.64 (1.97–16.18) - 12 0.001
Renal failure 4 (1.7) 7 (3.3) 1.88 (0.59–6.34) - 65 0.308
CrCl ‡ 30 to < 60 mL/min XOI 1 PBO
N = 510
XOI 1 LES400
N = 508
RR (95% CI) NNT p
Events (%)
N = 101
Events (%)
N = 92
Increased sCr 6 (5.9) 10 (10.9) 1.83 (0.69–4.84) - 20 0.223
Renal failure 5 (5.0) 7 (4.2) 0.87 (0.24–3.17) - 166 0.843
CrCl creatinine clearance, Increased sCr serum creatinine more than 1.5 9 baseline value, RR relative risk or risk ratio
(absolute risk for the event in the active group/absolute risk for the event in the control group), NNT number needed to
treat (- for harm, ? for beneﬁt), XOI xanthine oxidase inhibitor, PBO placebo, LES200 lesinurad 200 mg once a day,
LES400 lesinurad 400 mg once a day
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as recommended by the Cochrane collaboration
to evaluate interventions [12]. Patient-year
exposure was similar for all groups, as was the
number of patients allocated to each group,
thus facilitating unbiased estimates.
In each analysis, we found that the RRs for
LES 200 mg vs. placebo and LES 400 mg vs pla-
cebo decreased substantially with worsening
kidney function, suggesting that the risk of
adverse renal events diminished or was elimi-
nated in patients with moderate kidney
impairment. If lesinurad exhibited direct
nephrotoxicity [5], an increased risk of adverse
events in patients with the worst kidney func-
tion would be expected, as happens with
NSAIDs [14]. In contrast, we observed a pattern
of decreasing relative risk of adverse renal
events with decreasing eGFR, suggesting that
chronic kidney disease (CKD) is associated with
pathophysiological changes that may protect
against any potential nephrotoxicity associated
with lesinurad/XOI combinations. By contrast,
the US [6] and EU [7] recommend either not
prescribing in some patients with moderate
renal impairment (GFR\45 ml/min) or taking
special precautions if it is prescribed,
respectively.
Risk factors for adverse renal events associ-
ated with the use of uricosuric medications
include the filtered load of uric acid (the
product of the serum urate concentra-
tion 9 GFR), urinary pH (related to the acidifi-
cation capacity), and urinary acid concentration
(related to the concentration capacity). Indeed,
higher clearance of uric acid (associated with
better renal function) and undissociated urinary
urate (related to both acidic urinary pH and the
urinary uric acid concentration) have both been
associated with an increased risk of
nephrolithiasis during uricosuric treatment in
monotherapy [15]. Moreover, the appearance of
altered urine sediment, namely the presence of
red cells, while starting uricosuric medications
was also associated with increased urine density
and urinary creatinine and uric acid concen-
trations [16]. Patients with significant CKD have
reduced eGFR, a reduced capacity to concen-
trate urine, and a decreased capacity to acidify
urine [17, so they should benefit from a collec-
tive reduction in major risk factors for urate-
induced adverse events. Moreover, the con-
comitant use of a XOI with lesinurad reduces
the serum urate concentration and therefore
the filtered load of uric acid in the glomerulus
[18].
Although not derived from this analysis, our
empirical approach as precticing clinicians to
the renal safety of lesinurad treatment—until
further and specifically derived evidence is
available—is to encourage adherence to the XOI
Fig. 1 Plot showing that the incidence rate of increased
serum creatinine increased with decreasing eGFR, but that
the RR decreased with decreasing eGFR (because the
incidence rate of increased serum creatinine increases more
rapidly with decreasing eGFR in the PBO arm than in the
LES arms). RR relative risk, PBO placebo, LES lesinurad
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treatment when used in combination with
lesinurad, to ensure that adequate fluid intake is
maintained, initial evaluation followed by reg-
ular surveillance or renal function is untertaken
at least using spot urine samples for analysis
including abnormals, uric acid, creatinine,
density, and pH for all patients, as we used to do
with other uricosurics.
CONCLUSIONS
The rate of adverse renal events was similar in
the placebo and lesinurad 200 mg groups, while
the rates of renal failure and nephrolithiasis
were numerically lower in the lesinurad 200 mg
group than in the placebo group. The risk ratio
of sCri with lesinurad versus placebo decreased
with worsening renal function.
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